AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

LON:PRMProteome Sciences Share Price, Forecast & News

GBX 4.19
-0.01 (-0.24 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
3.90
Now: GBX 4.19
4.42
50-Day Range
3.35
MA: GBX 3.75
4.20
52-Week Range
2.25
Now: GBX 4.19
7
Volume192,440 shs
Average Volume88,695 shs
Market Capitalization£12.37 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers. It delivers content for personalized medicine in the areas of biomarker services, isobaric reagents, and biomarkers. The company designs, performs, and interprets high resolution proteomics studies to improve target discovery, validation, and mechanism of action studies; offers specialized services to enhance discovery and validation of mechanistic biomarkers in peripheral fluids; and provides a set of bioinformatics tools to enhance data integration, and select regulated features and map to biological processes. It primarily serves pharmaceutical companies and other sectors, including academic research. The company was incorporated in 1993 and is headquartered in London, the United Kingdom.
Read More
Proteome Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.40 out of 5 stars


Industry, Sector and Symbol

Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-70432116

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£4.66 million
Cash FlowGBX 0.32 per share
Book ValueGBX (1.20) per share

Profitability

Miscellaneous

Employees29
Market Cap£12.37 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PRM News and Ratings via Email

Sign-up to receive the latest news and ratings for PRM and its competitors with MarketBeat's FREE daily newsletter.

Proteome Sciences (LON:PRM) Frequently Asked Questions

How has Proteome Sciences' stock been impacted by COVID-19 (Coronavirus)?

Proteome Sciences' stock was trading at GBX 3.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PRM shares have increased by 28.9% and is now trading at GBX 4.19. View which stocks have been most impacted by Coronavirus.

How were Proteome Sciences' earnings last quarter?

Proteome Sciences plc (LON:PRM) posted its quarterly earnings data on Tuesday, April, 14th. The company reported $0.05 EPS for the quarter. View Proteome Sciences' earnings history.

Has Proteome Sciences been receiving favorable news coverage?

Headlines about PRM stock have been trending negative on Monday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Proteome Sciences earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Proteome Sciences.

Who are some of Proteome Sciences' key competitors?

What other stocks do shareholders of Proteome Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteome Sciences investors own include ValiRx (VAL), Boohoo Group (BOO), Mondi (MNDI), Petrofac (PFC), Lloyds Banking Group (LLOY), Falanx Group (FLX), Quanterix (QTRX), Centrica (CNA), Cyanconnode (CYAN) and Eckoh (ECK).

Who are Proteome Sciences' key executives?

Proteome Sciences' management team includes the following people:
  • Dr. Jeremy Rupert Michael Haigh, CEO & Exec. Director (Age 58)
  • Dr. Ian H. Pike, Chief Scientific Officer & Exec. Director
  • Mr. Richard Paul Dennis, Chief Commercial Officer & Exec. Director (Age 60)
  • Mr. Stefan Fuhrmann, Interim Fin. Director
  • Dr. Josef Schwarz, Chief Compliance Officer

What is Proteome Sciences' stock symbol?

Proteome Sciences trades on the London Stock Exchange (LON) under the ticker symbol "PRM."

How do I buy shares of Proteome Sciences?

Shares of PRM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Proteome Sciences' stock price today?

One share of PRM stock can currently be purchased for approximately GBX 4.19.

How big of a company is Proteome Sciences?

Proteome Sciences has a market capitalization of £12.37 million and generates £4.66 million in revenue each year. Proteome Sciences employs 29 workers across the globe.

What is Proteome Sciences' official website?

The official website for Proteome Sciences is www.proteomics.com.

How can I contact Proteome Sciences?

Proteome Sciences' mailing address is Hamilton House, Mabledon Place, LONDON, WC1H 9BB, United Kingdom. The company can be reached via phone at +44-20-70432116.

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.